

2023 Outpatient Infusion Services: SOC Contract List of Drug Codes

| Groupings | Trade Name | Drug Name | HCPCS |
|---|-------------------------------------|-----------------------------------|---------|
| Various Therapeutic Drugs | | | |
| | Actemra® | tocilizumab | J3262 * |
| | Adakveo® | crizanlizumab | J0791 |
| | Benlysta® | belimumab | J0490 * |
| | Cinqair® | reslizumab | J2786 |
| | Cinvanti® | aprepitant | J0185 |
| | Crysvita® | burosumab-twza | J0584 |
| | Enjaymo® | sutimilimab | J1302 |
| | Entyvio® | vedolizumab | J3380 |
| | Evenity® | romosozumab | J3111 |
| | Givlaari® | givosiran | J0223 |
| | Krystexxa® | pegloticase | J2507 |
| | Mozobil® | plerixafor | J2562 |
| | Ocrevus® | ocrelizumab | J2350 |
| | Onpattro® | patisiran | J0222 |
| | Opdivo® | nivolumab | J9299 |
| | Orencia® | abatacept | J0129 |
| | Prolia®, Xgeva® | denosumab | J0897 |
| | Radicava® | edaravone | J1301 |
| | Reblozyl® | luspatercept | J0896 |
| | Sandostatin® LAR Depot | octreotide depot IM | J2353 |
| | Saphnelo® | anifrolumab-fnia | J0491 |
| | Simponi Aria® | golimumab | J1602 |
| | Soliris® | eculizumab | J1300 |
| | Somatuline® Depot | lanreotide | J1930 |
| | Spinraza® | nusinersen | J2326 |
| | Tepezza® | teprotumumab-trbw | J3241 |
| | Trogarzo® | ibalizumab-uiyk | J1746 |
| | Tysabri® | natalizumab | J2323 |
| | Ultomiris® | ravulizumab-cwvz | J1303 |
| | Uplizna® | inebilizumab | J1823 |
| | Viltepso® | viltolarsen | J1427 |
| | Vyepti® | eptinezumab-jjmr | J3032 |
| | Vyvgart® | efgartigimod | J9332 |
| | Yervoy® | ipilimumab | J9228 |
| | | Unclassified Drugs or Biologicals | C9399 |
| | | Unclassified Biologics | J3590 |
| | | Unclassified Drugs | J3490 |
| Alpha-1 proteinase inhibitor | | | |
| | Aralast® NP, Prolastin-C®, Zemaira® | alpha-1 proteinase inhibitor | J0256 |
| | Glassia® | alpha-1 proteinase inhibitor | J0257 |
| Bevacizumab (Avastin®) biosimilars | | | |

| | | | |
|-------------------------------------|-------------------------------------|--------------------------------------|-------|
| | Alymsys® | bevacizumab-maly | Q5126 |
| | Mvasi® | bevacizumab-awwb | Q5107 |
| | Zirabev® | bevacizumab-bvzr | Q5118 |
| C-1 esterase inhibitor | | | |
| | Berinert® | C-1 esterase inhibitor (human) | J0597 |
| | Cinryze® | C-1 esterase inhibitor (human) | J0598 |
| | Ruconest® | C-1 esterase inhibitor (recombinant) | J0596 |
| Enzyme Replacement Therapies | | | |
| | Aldurazyme® | laronidase | J1931 |
| | Cerezyme® | Imiglucerase | J1786 |
| | Elaprase® | idursulfase | J1743 |
| | Elelyso® | taliglucerase alfa | J3060 |
| | Fabrazyme® | agalsidase beta | J0180 |
| | Kanuma® | sebelipase alfa | J2840 |
| | Lumizyme® | alglucosidase alfa | J0221 |
| | Mepsevii® | vestronidase alfa-vjvk | J3397 |
| | Naglazyme® | galsulfase | J1458 |
| | Nexviazyme® | avalglucosidase alfa-ngpt | J0219 |
| | Vimizim® | elosulfase alfa | J1322 |
| | VPRIV® | velaglucerase alfa | J3385 |
| Filgrastim and biosimilars | | | |
| | Granix® | tbo-filgrastim | J1447 |
| | Neupogen® | filgrastim, excludes biosimilars | J1442 |
| | Nivestym® | filgrastim-aafi | Q5110 |
| | Releuko® | filgrastim-ayow | Q5125 |
| | Zarxio® | filgrastim-sndz | Q5101 |
| Immune Globulins | | | |
| | Asceniv® | immune globulin | J1554 |
| | Bivigam® | immune globulin | J1556 |
| | Carimune® NF, Gammagard® S/D | immune globulin | J1566 |
| | Cutaquig® | immune globulin | J3590 |
| | Cuvitru® | immune globulin | J1555 |
| | Flebogamma®, Flebogamma® DIF | immune globulin | J1572 |
| | Gammagard® | immune globulin | J1569 |
| | Gammaked®, Gamunex-C® | immune globulin | J1561 |
| | Gammaplex® | immune globulin | J1557 |
| | Hizentra® | immune globulin | J1559 |
| | Hyqvia® | immune globulin | J1575 |
| | IVIG non-lypholized, NOS (Panzyga®) | immune globulin | J1599 |
| | Octagam® | immune globulin | J1568 |
| | Privigen® | immune globulin | J1459 |
| | Xembify® | immune globulin | J1558 |
| Infliximab and biosimilars | | | |
| | Avsola® | infliximab-axxq | Q5121 |
| | Inflectra® | infliximab-dyyb | Q5103 |
| | Ixifi® | infliximab-qbtx | Q5109 |

| | | | |
|---|--------------------|-----------------------------------|-------|
| | Remicade® | infliximab, excludes biosimilars | J1745 |
| | Renflexis® | infliximab-abda | Q5104 |
| Iron Injectables | | | |
| | Feraheme® | feromoxytol, non-esrd | Q0138 |
| | Infed® | iron dextran | J1750 |
| | Injectafer® | ferric caboxymaltose | J1439 |
| Pegfilgrastim and biosimilars | | | |
| | Fulphila® | pegfilgrastim-jmdb | Q5108 |
| | Neulasta® | pegfilgrastim | J2506 |
| | Nyvepria® | pegfilgrastim | Q5122 |
| | Udenyca® | pegfilgrastim-cbqv | Q5111 |
| | Ziextenzo® | pegfilgrastim-bmez | Q5120 |
| Rituximab (Rituxan®) biosimilars | | | |
| | Riabni® | rituximab-arrx | Q5123 |
| | Ruxience® | rituximab-pvvr | Q5119 |
| | Truxima® | rituximab-abbs | Q5115 |
| Rituximab containing drugs | | | |
| | Rituxan® Hycela | rituximab and hyaluronidase | J9311 |
| Trastuzumab (Herceptin®) biosimilars | | | |
| | Herzuma® | trastuzumab-pkrb | Q5113 |
| | Kanjinti® | trastuzumab-anns | Q5117 |
| | Ogiviri® | trastuzumab-dkst | Q5114 |
| | Ontruzant® | trastuzumab-dttb | Q5112 |
| | Trazimera® | trastuzumab-qyyp | Q5116 |
| Trastuzumab containing drugs | | | |
| | Enhertu® | fam-trastuzumab deruxtecan-nxki | J9358 |
| | Herceptin® Hylecta | trastuzumab and hyluronidase-oysk | J9356 |
| | Kadcyla® | ado-trastuzumab emtansine | J9354 |

***Coding/Billing: Route of administration modifier - JA and -JB**

Claim denials may occur when the appropriate modifier is not applied to a J code/medication, which has more than one route of administration

JA - Intravenous administration

JB - Subcutaneous administration

Published

9/27/2022

Last update (new HCPCS codes released)

11/28/2022